lenalidomide — Medica
Histiocytic Neoplasms (Langerhans cell histiocytosis, Rosai-Dorfman disease)
Initial criteria
- age ≥ 18 years
- EITHER (a) patient has Langerhans cell histiocytosis AND has single-system multifocal skin disease OR relapsed or refractory disease; OR (b) patient has Rosai-Dorfman disease
Approval duration
1 year